mitoxantrone has been researched along with Necrosis in 11 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitoxantrone (MX) is a cytotoxic drug with proven clinical efficacy in active multiple sclerosis (MS)." | 7.73 | Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. ( Chan, A; Gold, R; Toyka, KV; Weilbach, FX, 2005) |
| "Mitoxantrone (MX) is a cytotoxic drug with proven clinical efficacy in active multiple sclerosis (MS)." | 3.73 | Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. ( Chan, A; Gold, R; Toyka, KV; Weilbach, FX, 2005) |
| "Mitoxantrone (Novantrone), is an anthracenedione which in preclinical studies demonstrated a spectrum of antitumor activity similar to the anthracyclines, but with less cardiotoxicity." | 2.66 | Mitoxantrone: an overview of safety and toxicity. ( Bernstein, T; Cartwright, K; Dukart, G; Goldberg, J; Posner, LE, 1985) |
| "Aclarubicin was the fastest acting drug, inducing DNA fragmentation 12 h earlier than doxorubicin, and 24 h earlier than mitoxantrone." | 1.33 | Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation. ( Jedrzejczak, M; Jóźwiak, Z; Kania, K; Koceva-Chyła, A; Skierski, J, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thomadaki, H | 1 |
| Mavridis, K | 1 |
| Talieri, M | 1 |
| Scorilas, A | 1 |
| Chan, A | 1 |
| Weilbach, FX | 1 |
| Toyka, KV | 1 |
| Gold, R | 1 |
| Luke, E | 1 |
| Koceva-Chyła, A | 1 |
| Jedrzejczak, M | 1 |
| Skierski, J | 1 |
| Kania, K | 1 |
| Jóźwiak, Z | 1 |
| Dreosti, LM | 1 |
| Bezwoda, W | 1 |
| Gunter, K | 1 |
| Görich, J | 1 |
| Brensing, KA | 1 |
| Kunze, V | 1 |
| Sokiranski, R | 1 |
| Rilinger, N | 1 |
| Müller-Miny, H | 1 |
| Brambs, HJ | 1 |
| Levin, M | 1 |
| Caravone, D | 1 |
| Geiser, C | 1 |
| Nachbaur, K | 1 |
| Dietze, O | 1 |
| Herold, M | 1 |
| Thaler, J | 1 |
| Braunsteiner, H | 1 |
| Vogel, W | 1 |
| Carneskog, J | 1 |
| Westin, J | 1 |
| Lauritzen, C | 1 |
| Ketelbey, JW | 1 |
| Posner, LE | 1 |
| Dukart, G | 1 |
| Goldberg, J | 1 |
| Bernstein, T | 1 |
| Cartwright, K | 1 |
1 trial available for mitoxantrone and Necrosis
| Article | Year |
|---|---|
Mitoxantrone: an overview of safety and toxicity.
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Clini | 1985 |
10 other studies available for mitoxantrone and Necrosis
| Article | Year |
|---|---|
Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Su | 2009 |
Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients.
Topics: Adult; Antigens, CD19; Apoptosis; B-Lymphocytes; CD3 Complex; Cell Division; Cells, Cultured; Female | 2005 |
Mitoxantrone-induced extravasation.
Topics: Antineoplastic Agents; Extravasation of Diagnostic and Therapeutic Materials; Humans; Male; Middle A | 2005 |
Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation.
Topics: Aclarubicin; Animals; Antineoplastic Agents; Apoptosis; Bisbenzimidazole; Caspase 3; Caspase Inhibit | 2005 |
Bone marrow necrosis following ALL-trans retinoic acid therapy for acute promyelocytic leukaemia.
Topics: Bone Marrow; Female; Humans; Immunologic Factors; Leukemia, Promyelocytic, Acute; Leukocyte Count; L | 1994 |
[Percutaneous drainage of refractory necrotizing tumors: experience in 9 patients].
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Cystadenocarcinoma; Drainage; Female; His | 1995 |
Mitoxantrone extravasation and tissue necrosis.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Capillary Leak Syndrome; Female; Humans; Injections, | 1996 |
Fulminant hepatic failure after high-dose cytosine arabinoside and mitoxantrone treatment for relapse of acute myelogenous leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans | 1992 |
[Even mitoxantrone can cause local skin necrosis].
Topics: Humans; Male; Middle Aged; Mitoxantrone; Necrosis; Skin | 1990 |
Cytotoxic-drug extravasation.
Topics: Blister; Humans; Mitoxantrone; Necrosis | 1989 |